Evaluating the combination of amoxicillin, gemifloxacin and rabeprazole therapy for Helicobacter pylori eradication in young and older adult patients

Basit Öğe Kaydı
dc.contributor.authorKilic, Güner E.
dc.contributor.authorKilic, Gulce Ecem
dc.contributor.authorKayar, Nüket Bayram
dc.contributor.authorDurmaz, Ozan
dc.contributor.authorÖzkahraman, Adnan
dc.contributor.authorKonür, Şevki
dc.contributor.authorDertli, Ramazan
dc.date.accessioned2025-10-11T20:45:33Z
dc.date.available2025-10-11T20:45:33Z
dc.date.issued2024
dc.departmentDüzce Üniversitesien_US
dc.description.abstractPurpose: To assess the effectiveness, safety and adverse effects of treatment regimen combining amoxicillin, gemifloxacin and rabeprazole for eradicating Helicobacter pylori in adult population. Methods: A total of 211 patients comprising 33 patients (15.6 %) from the older adult group and 178 patients (84.4 %) from the younger adult group who visited Van Training and Research Hospital, Turkey were included in this study. Treatment, made up of amoxicillin (1000 mg) and rabeprazole (20 mg), was administered 12 hourly and gemifloxacin (320 mg) once daily to all patients for 7 days. Thereafter, patients were evaluated for H. pylori eradication by examining antigens in feces (immunochromatographically based, qualitatively), drug compliance and treatment tolerance. Results: Post-treatment investigations showed that H. pylori was completely eradicated in 187 patients (88.6 %), while eradication was not achieved in 24 patients (11.4 %). In the older adult group, H. pylori was successfully eradicated in 27 of 33 patients (81.8 %). Excluding a total of 9 patients who did not complete treatment due to side effects, H. pylori eradication was achieved in 184 of 202 patients (91 %). Conclusion: This combination of three antibiotics exhibits a high rate of eradication of H. pylori among adult patients, even when administered for a short period (one week). This investigation should be carried out using a larger and more diverse patient population to validate the outcomes reported in this study. © 2025 Elsevier B.V., All rights reserved.en_US
dc.identifier.doi10.4314/tjpr.v23i12.12
dc.identifier.endpage2078en_US
dc.identifier.issn1596-9827
dc.identifier.issn1596-5996
dc.identifier.issue12en_US
dc.identifier.scopus2-s2.0-85214394455en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2073en_US
dc.identifier.urihttps://doi.org/10.4314/tjpr.v23i12.12
dc.identifier.urihttps://hdl.handle.net/20.500.12684/21418
dc.identifier.volume23en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherUniversity of Beninen_US
dc.relation.ispartofTropical Journal of Pharmaceutical Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_Scopus_20250911
dc.subjectAdult Patientsen_US
dc.subjectAmoxicillinen_US
dc.subjectGemifloxacinen_US
dc.subjectHelicobacter Pylorien_US
dc.subjectRabeprazoleen_US
dc.subjectAmoxicillinen_US
dc.subjectGemifloxacinen_US
dc.subjectKetamineen_US
dc.subjectLidocaineen_US
dc.subjectMidazolamen_US
dc.subjectRabeprazoleen_US
dc.subjectG5300wr Endoscopeen_US
dc.subjectSpss Version 24.0en_US
dc.subjectAmoxicillinen_US
dc.subjectGemifloxacinen_US
dc.subjectKetamineen_US
dc.subjectLidocaineen_US
dc.subjectMidazolamen_US
dc.subjectRabeprazoleen_US
dc.subjectAbdominal Painen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectArticleen_US
dc.subjectBacterial Clearanceen_US
dc.subjectBloatingen_US
dc.subjectBody Massen_US
dc.subjectConstipationen_US
dc.subjectControlled Studyen_US
dc.subjectDiarrheaen_US
dc.subjectDysplasiaen_US
dc.subjectFatigueen_US
dc.subjectFemaleen_US
dc.subjectGastrointestinal Endoscopyen_US
dc.subjectHelicobacter Infectionen_US
dc.subjectHelicobacter Pylorien_US
dc.subjectHistopathologyen_US
dc.subjectHumanen_US
dc.subjectHuman Tissueen_US
dc.subjectImmunoaffinity Chromatographyen_US
dc.subjectInflammationen_US
dc.subjectIntestinal Metaplasiaen_US
dc.subjectMajor Clinical Studyen_US
dc.subjectMaleen_US
dc.subjectMedication Complianceen_US
dc.subjectMiddle Ageden_US
dc.subjectNausea And Vomitingen_US
dc.subjectRashen_US
dc.subjectRetrospective Studyen_US
dc.subjectSedationen_US
dc.subjectSomnolenceen_US
dc.subjectStomach Tissueen_US
dc.titleEvaluating the combination of amoxicillin, gemifloxacin and rabeprazole therapy for Helicobacter pylori eradication in young and older adult patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu